Enspryng helps patients remain relapse-free after 6 months: Study
Nearly all neuromyelitis optica spectrum disorder patients on Enspryng remain free from relapses after six months, a real-world study in Japan shows.| Neuromyelitis News
Nearly all neuromyelitis optica spectrum disorder patients on Enspryng remain free from relapses after six months, a real-world study in Japan shows.| Neuromyelitis News
The findings support the idea that gut microbiota and the gut-brain axis factor in NMOSD, and that approaches like GV-971 may help patients.| Neuromyelitis News
Higher levels of the signaling molecule CXCL13 detected in the blood and CSF fluid of NMOSD patients were accompanied by worse disability.| Neuromyelitis News
NMOSD is among autoimmune disease risk factors, with patients at about nine times the risk of developing another condition, per a study.| Neuromyelitis News
Rituximab and mycophenolate mofetil may offer the most effective off-label alternatives for NMOSD patients, according to a study.| Neuromyelitis News
The platelet-to-lymphocyte ratio may be used as a biomarker of disability severity in people with NMOSD, a study found.| Neuromyelitis News
Margarida Maia is a science writer for Neuromyelitis News with a PhD in biomedical sciences. She covers the latest news and information on a variety of NMO topics.| Neuromyelitis News
NMOSD patients who are positive for the anti-AQP4 antibodies were more likely to have other autoimmune diseases, a study in Argentina shows.| Neuromyelitis News
A new predictive model to identify neuromyelitis optica spectrum disorder patients at a higher risk of relapse was found accurate in a study.| Neuromyelitis News
A Phase 1 clinical study tested the therapy in 15 patients positive for antibodies against AQP4, those most commonly associated with NMOSD.| Neuromyelitis News
Category archive page for News.| Neuromyelitis News
